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Abstract—The ﬁeld of regenerative medicine has progressed
tremendously over the past few decades in its ability to
fabricate functional tissue substitutes. Conventional
approaches based on scaffolding and microengineering are
limited in their capacity of producing tissue constructs with
precise biomimetic properties. Three-dimensional (3D) bio-
printing technology, on the other hand, promises to bridge
the divergence between artiﬁcially engineered tissue con-
structs and native tissues. In a sense, 3D bioprinting offers
unprecedented versatility to co-deliver cells and biomaterials
with precise control over their compositions, spatial distri-
butions, and architectural accuracy, therefore achieving
detailed or even personalized recapitulation of the ﬁne shape,
structure, and architecture of target tissues and organs. Here
we brieﬂy describe recent progresses of 3D bioprinting
technology and associated bioinks suitable for the printing
process. We then focus on the applications of this technology
in fabrication of biomimetic constructs of several represen-
tative tissues and organs, including blood vessel, heart, liver,
and cartilage. We ﬁnally conclude with future challenges in
3D bioprinting as well as potential solutions for further
development.
Keywords—Bioprinting, Additive manufacturing, Bioink,
Tissue engineering, Regenerative medicine.
INTRODUCTION
Tissue engineering has emerged as a promising
solution to the unmet demand of tissues and organs for
regenerative medicine and pharmaceutical research.
Tissue engineering uses a combination of cells, bio-
materials, and engineering technologies to fabricate
biological constructs that mimic and improve the
functions of their counterparts in human
body.7,52,59–61,72,101,125 The concept and scope have
signiﬁcantly expanded during the past decades, leading
to widespread applications such as regeneration of
damaged tissues in vivo that are beyond the ability of
self-repairing in the conventional sense, as well as
construction of in vitro models for understanding cel-
lular behaviors and performing drug screening using
microﬂuidic organs-on-a-chip platforms, among many
others. While several poorly vascularized tissues such
as cornea90 are less complicated to engineer, fabrica-
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tion of most other tissues relies on high density of
multiple cell types to achieve full recapitulation of
tissue/organ-level functions (Fig. 1a).
A variety of tissue engineering strategies have been
developed to tackle the challenges for regenerating
or modeling highly complex and functional tis-
sues.1,72,99,101,125 The conventional methodology
makes use of scaffolds as matrices to load cells
(Fig. 1b).67 These scaffolds can be fabricated from ei-
ther naturally derived polymers such as gelatin,24,46,88
collagen,14,39,46 hyaluronic acid,12,46 and alginate,2,24,46
or synthetic polymers such as poly(e-caprolactone)
(PCL), poly(lactic acid) (PLA), poly(glycolic acid)
(PGA), and poly(lactic-co-glycolic acid)
(PLGA).47,49,69,108,123 The scaffolds serve as three-di-
mensional (3D) templates that support cells to attach,
proliferate, and expand throughout the entire structure
before they develop their own extracellular matrix
(ECM), which eventually leads to the generation of
mature cell-laden grafts with comparable properties to
their native counterparts. Studies have shown that the
phenotypes of seeded cells can be regulated in the
scaffolds by applying a combination of different bio-
logical and physical stimuli, including growth fac-
tors,99,114 shear stress,89,100 as well as electrical93,112,122
and mechanical cues.31,48,53,119 However, there are
limitations for these conventional scaffold-based
approaches, including the intrinsic inability to mimic
the complex microstructures of biological tissues.67
Particularly, it is widely acknowledged that physio-
logically relevant activities and functions of organs
critically rely on their microarchitectures, such as the
capillaries of the nephron system in kidneys,104 the
hepatic lobules of livers,44 and the aligned cardiac ﬁ-
bers of the myocardium.16,122
Alternatively, the modular tissue engineering
methodology aims to mimic the microstructural fea-
tures of native tissues and organs.25,29,67 In this
approach, the complex architecture of a tissue con-
struct is divided into basic functional building blocks,
which can be further assembled unit by unit into
larger biomimetic structures. One distinctive advantage
of the modular approach lies in its ability to precisely
produce microscopic structural features, allowing for
subsequent assembly in a controlled manner
(Fig. 1b).29,67
Among diﬀerent approaches, the recently developed
3D bioprinting technology promises to bridge the
divergence between artiﬁcially engineered tissue con-
structs and native tissues. It is believed that 3D bio-
printing oﬀers unprecedented versatility and capability
to deliver cells and biomaterials with precise control
over spatial distributions. As a result, it is possible to
recreate engineered constructs with accurate, detailed,
FIGURE 1. Approaches for tissue/organ fabrication. (a) Scale of cell numbers encountered in tissue engineering spans at least
eight orders of magnitude. The minimum therapeutic threshold for recapitulating solid organ functions in humans is estimated at
the level of 1–10 billion functioning cells. Reproduced with permission from Ref. 76, copyright 2014 public library of science. (b)
Schematic illustrations of common approaches for tissue engineering. In the scaffold-based approach, cells are seeded into a
porous scaffold to populate the matrix and deposit their own ECM. The modular approach, on the other hand, building blocks are
utilized to build up large tissue constructs via multiple assembling techniques. Reproduced with permission from Ref. 68,
copyright 2013 Dove Medical Press.
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or even personalized features that mimic the ﬁne shape,
structure, architecture, and therefore, function of tar-
geting tissues and organs.70,83 In general, current 3D
bioprinting technologies can be divided into indirect
and direct fabrications. Indirect 3D bioprinting ﬁrst
creates negative sacriﬁcial molds, followed by casting
with desired positive biomaterial and then selective
removal of the molds.6,57,63,77 Direct 3D bioprinting
techniques, on the other hand, generate 3D structures
in a point-by-point and/or layer-by-layer manner,
which offer feasibility in depositing multiple cell types
and/or biomaterials to achieve tissue constructs with
improved reproducibility and heterogeneity to mimic
in vivo systems.83
In this review we brieﬂy describe recent progresses
of 3D bioprinting technology and associated bioinks
suitable for the printing process. We then focus on
the applications of this versatile technology, in fab-
rication of biomimetic constructs of several repre-
sentative tissues and organs that have been widely
explored for live cell deposition, including blood
vessel, heart, liver, and cartilage, largely due to the
unique challenges associated with construction of
these highly complex biological structures using
conventional tissue engineering approaches. We ﬁ-
nally conclude with future challenges in 3D bio-
printing and perspectives.
FROM BLUEPRINTS TO GRAFTS
Typically, 3D bioprinting starts with a computer-
assisted process for depositing biomaterials and living
cells in a determinate conﬁguration in order to produce
a deﬁned 3D biological structure.80,83 The general
process contains three steps: (i) pre-processing for
acquisition of 3D computer-aided design (CAD) model
of the tissue to be engineered; (ii) processing by auto-
mated deposition of cells and/or biomaterials of
interest; and (iii) post-processing involving maturation
of cell-laden constructs to reinforce the development of
desired tissue constructs.78,79,83
Many current imaging and diagnostic technologies,
such as magnetic resonance imaging (MRI) and com-
puter tomography (CT), have been explored to acquire
information about the targeting tissues and achieve the
CAD ‘‘blueprints’’ of the grafts.83 The 3D CAD
models can be subsequently segregated into 2D hori-
zontal slices to provide instructions to the bioprinter
and direct the layer-by-layer depositions of the bio-
logical elements.79,83 In addition to an appropriate
software that coordinates the deposition, the other key
component of a bioprinting system include the bioink,
which refers to the (cell-laden) biomaterials used as the
ink for the bioprinters.79,83
SELECTION OF BIOINKS
Selection of proper biomaterials as the bioink is a
key step towards successful bioprinting. Bioinks based
on both naturally derived and synthetic biomaterials
have been developed to aﬀord a spectrum of proper-
ties, such as biocompatibility and appropriate physical
assets, to ensure printability and long-term function-
ality following deposition.18,83,84,109 For example, vis-
cosity of the bioink is an important rheological
parameter to determine ﬂexibility in deposition of free-
standing structures and maintenance of architectural
integrity immediately after bioprinting.18,57 Shear-
thinning biomaterials such as those based on Pluronic,
gelatin, polyethylene glycol (PEG), or their combina-
tions with other hydrogels, are often utilized as
bioinks, which possess a liquid-like behavior under
high shear stress during the extrusion process, but can
quickly recover their gel state once bioprinted and thus
prevent the structure from collapsing.8,42,43,57 Long-
term stability of the bioprinted tissue constructs,
however, typically depends on a secondary crosslink-
ing mechanism to further stabilize the bioprinted
structures.19 There are two general crosslinking
mechanisms: (i) physical crosslinking through non-
covalent interactions such as thermally induced sol–gel
transitions or ionic interactions, and (ii) chemical
crosslinking through the formation of new covalent
bonds.70 For example, it is well-known that alginate
solutions can be quickly crosslinked in the presence of
Ca2+ ions to form a solid physical hydrogel.2,17 Other
systems such as gelatin methacryloyl (GelMA) hydro-
gels can be photocrosslinked to form permanent 3D
polymeric networks in the presence of a photoinitiator
upon light exposure.88,121 Since physically crosslinked
gels are typically unstable over an extended period of
time and are subject to dissolution, they can function
effectively as fugitive templates where only temporal
stability is required, such as in cases of fabricating
sacriﬁcial bioprinted constructs like the vasculature
systems.6,57,63,77 In contrast, chemically crosslinked
gels possess better long-term stability and are suit-
able for constructive bioprinting to function as the
biomimetic ECM.
To date, hydrogels based on natural biopolymers,
such as alginate,17,19 gelatin,8,19,63 collagen,64,65,110
ﬁbrin,110 hyaluronic acid,42 chitosan,82 and agarose,6
as well as many synthetic polymers like PEG15,21 and
Pluronic,57 have been demonstrated to fulﬁll some
essential requirements for use as bioinks. These
bioinks may not only provide the basis as sacriﬁ-
cial/constructive scaffolds, but can also maintain the
viability and promote the activity of bioprinted living
cells. Recently, decellularized extracellular matrix
(dECM), a class of naturally derived composite bio-
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materials, has attracted increasing attention for their
use as bioinks (Fig. 2a).83,95 One unique advantage of
the dECM bioinks lies in the ability to apply materials
from the same tissue of interest in the bioprinting
process, which promises to present well-matched
compositional complexity in addition to architectural
ﬁdelity between the printed biological structures and
the target tissues (Fig. 2b).83
Besides biomaterials, encapsulated cells comprise
another critical component of bioinks. The cells need
to be widely available due to the fact that bioprinting
generally requires large densities of cells to maintain
post-printing functionality.76 In addition, the cells
should be able to survive under the high shear stress
caused by the viscous bioink during the bioprinting
process, and resist the relatively harsh crosslinking
steps (e.g., in the presence of chemical reagents or UV
light) associated with the design of bioinks.83 Indeed, it
has been shown that short-time exposure to high levels
of shear stress during the bioprinting procedure could
both affect immediately cell viability as well as induce
long-term alterations in the proliferation and poten-
tially functionality of those that have survived the
bioprinting process; for a certain cell type a speciﬁc
threshold of shear stress may exist without noticeable
side effects.11 It is further expected that mature somatic
cell types in general are more resistant to these harsh
environments than stem cells, which tend to respond to
externally applied physical stimuli such as the
mechanics.31,48 To this end, an optimized shear rate for
FIGURE 2. 3D Bioprinting with dECM bioinks of different tissue constructs. (a) dECM materials are obtained from various tissues
via a multi-step decellularization process that combines physical, chemical and enzymatic treatments. The collected soluble dECM
materials are mixed with stem cells and used as bioinks in a layer-by-layer bioprinting approach to fabricate tissue analogues. (b)
Native tissues and bioprinted constructs from dECM of the corresponding tissues show similar morphological or histological
appearance. Reproduced with permission from Ref. 95, copyright 2014 Nature Publishing Group.
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dispensing of each cell type may be obtained by care-
fully tuning the extrusion rate of the bioink at a bal-
anced bioprinting speed to ensure high cell viability
and unaltered cell functions to support tissue forma-
tion.11 Shear stress that the cells experience during the
bioprinting process may also be adjusted by changing
the viscosity of the bioink.11,19 While most current
technologies focus on single-cell-type bioprinting, the
need for simultaneous deposition of multiple cells
types to mimic the in vivo scenario has been increas-
ingly acknowledged.19,40 Additionally, the cells can be
encapsulated as either individually dispersed cells or as
aggregates of cells (e.g., spheroids).9,22,81 While single-
cell bioprinting allows for better ﬂexibility in fabri-
cating tissues on smaller scales and requires less efforts
in the preparation of bioinks, the advantages related to
bioprinting spheroids include reduction of time to
produce larger tissues and much higher cell viability
due to the protection of cells in the interiors of
spheroids from the shear stress.9
BIOPRINTING THE VASCULATURE: FROM
EXPRESSWAYS TO ALLEYS IN THE BODY
Cells embedded in any tissue construct require
optimal nutrition and oxygen delivery, as well as re-
moval of produced wastes, to maintain viability and
functionality.3,91,92 Diffusion of growth factors and
other signaling biomolecules is also of critical impor-
tance to direct cellular behaviors. Large tissues and
organs are integrated with complex vasculature in vivo
that provides blood ﬂow to sustain all the necessary
supplies and functionalities. Therefore, introduction of
vessel-like structures is a prerequisite for successful
engineering of functional tissues suitable for regener-
ation as well as construction of in vitro models to
understand underlying disease causes and screen
pharmaceutical compounds.124
Native arteries and veins present a multi-layered
structure where blood ﬂow in the lumen is surrounded
by three layers of distinct components and cell types.
The innermost layer is called ‘tunica intima’, which is
formed by endothelial cells; the middle layer ‘tunica
media’ and the outmost ‘tunica externa’ layer are
composed of smooth muscle cells [SMCs] supported by
connective tissues of elastic and collagenous ﬁbers,
respectively (Fig. 3a).20,105 From a functional point of
view, however, in vitro vessels should possess at least
hollow lumens ideally covered by one or more layers of
undamaged endothelium and pericytes.92 Recently,
numerous approaches have been developed to recreate
vasculature in vitro. Although major efforts have been
devoted to understanding factors that promote vas-
cularization (i.e., angiogenic growth factors),98,99,102 it
remains highly challenging to induce the formation of
vessels with desired organization. A promising solution
is to create tissue constructs with pre-deﬁned
microarchitecture (such as interconnected microchan-
nels) that mimic the vasculature and support sur-
rounding stromal cells to survive and function. To
realize this aim, 3D bioprinting techniques have been
explored, which ensure precise control over the spatial
arrangements of the vascular cells in the matrix.
Scaﬀold-free vessel-like tubular structures have been
reported as potential vessel substitutes by direct 3D
bioprinting techniques. For example, Ozbolat et al.
used alginate solutions as the bioink, which could be
physically crosslinked by CaCl2 solutions. The two
solutions were delivered using a customized coaxial
needle to achieve in situ crosslinking upon deposition
of the bioinks to form lumen-like structures.126 In a
successive study, they further demonstrated the ability
of the bioprinted network to provide nutrients to
encapsulated cells in the surrounding matrix.120 Sig-
niﬁcantly, patient-inspired bioprinting of scaffold-free
macrovascular structures has been demonstrated by
Koc et al. MRI/CT data of the human aorta were
segmented and converted into a CAD model for the
bioprinter.58 Layer-by-layer printing of cylindrical
aggregates of cell-laden hydrogels in a supporting
structure consisted of crossing vertical and horizontal
rods, as illustrated in Fig. 3b.
While direct bioprinting of macrovessels represents
a breakthrough in generating blood vessels at larger
scales, fabrication of hollow vessels within cell-laden
tissue constructs is typically more complex and
requires entirely diﬀerent methodologies based on
sacriﬁcial bioprinting. A common strategy to sacriﬁ-
cially bioprint a vascularized tissue generally involves
three steps: (i) bioprinting of a network of solid ﬁbers
embedded in a hydrogel matrix encapsulating stromal
cells; (ii) selective removal of the ﬁbers to form per-
fusable channels; and (iii) seeding of endothelial cells in
the interiors of the channels to build functional ves-
sels.45 Such techniques to fabricate perfusable matrices
are also referred as indirect bioprinting, since they re-
quire the printing of sacriﬁcial templates in the
matrices that are subsequently removed to reveal the
hollow channel structures.
Khademhosseini et al. applied agarose, a naturally
derived polysaccharide, as the sacriﬁcial template to
bioprint hollow vessels within hydrogel constructs.6
Agarose solutions (>2 wt%) formed a solid gel be-
low 32 C to function as a fugitive bioink that could
be removed later on. A cell-laden hydrogel precursor
(SMCs and ﬁbroblasts in 5–20 wt% GelMA or
polyethylene glycol diacrylate [PEGDA] solution)
was then poured around the patterned agarose ﬁbers
and photocrosslinked to form the matrix. After sta-
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bilizing the construct, the agarose ﬁbers could be
removed under mild vacuum to obtain hollow
channels with diameters down to 100 lm (Fig. 3c).
The presence of these channels signiﬁcantly improved
the viability of the surrounding stromal cells in the
construct due to enhanced nutrient and oxygen
delivery. Signiﬁcantly, the bioprinted microchannels
might be further coated with a layer of endothelium
to recapitulate the biological function of the
microvasculature (Fig. 3ciii).
Direct retraction of the sacriﬁcial templates, however,
may compromise the integrity of the channels in tissue
constructs. To this end, an alternative bioink was
introduced by Lewis et al. that could be liqueﬁed by
simply tuning the temperature.57 Speciﬁcally, it was
found that Pluronic F127 solutions formed a shear-
thinning hydrogel at room temperature, but returned to
its solution state below 4 C. Therefore, Pluronic F127
solution was used as the fugitive bioink to bioprint mi-
croﬁbers at a higher temperature, while hollow channels
in the crosslinked GelMA hydrogel matrix could be ea-
sily generated by subsequently decreasing the tempera-
ture to remove the Pluronic F127 microﬁbers (Fig. 3d).
Although providing a simple strategy for the construc-
tion of hollow vessels, minor cytotoxic effects associated
with the use of high-concentration Pluronic-F127 solu-
tions were observed, which might partially limit its
applications in the fabrication of cell-laden constructs.
FIGURE 3. Bioprinting of vascular structures. (a) Physiology of arteries and veins. Arteries and veins sharing certain features in
the multi-layered structures but differ in many other ways. Reproduced with permission from Ref. 117, copyright 2011 John Wiley &
Sons. (b) Construction of macroscale vessels: (i) 3D bioprinted hydrogel; (ii) cross-sectional view; (iii) perspective view of the aorta
model. Reproduced with permission from Ref. 58, copyright 2013 Elsevier. (c) Templated bioprinting based on sacrificial agarose
fibers: (i) graphic mode of the agarose template fibers for micromolding; schematic representation of bioprinting of agarose
template fibers and subsequent formation of microchannels via template micromolding; (ii) bifurcating bioprinted microchannel
network in a GelMA hydrogel; and (iii) confocal image of HUVEC-lined microchannel generated by template micromolding. The
inset shows a cross-sectional view of the channel. Scale bars: 250 lm. Reproduced with permission from Ref. 6, copyright 2014
Royal Society of Chemistry. (d) Schematic views of a heterogeneous bioprinting based on fugitive Pluronics inks: (i) blue filament
corresponds to 10T1/2 fibroblast-laden GelMA, red fugitive filament, and green HNDF-laden GelMA ink; (ii) bright-field image of the
3D printed tissue construct, which is overlayed with the green fluorescent channel; (iii) stacked composition of tissue construct.
Reproduced with permission from Ref. 57, copyright 2014 Wiley–VCH. (e) Sacrificial bioprinting based on sugar struts: (i) sche-
matic overview of an bioprinted interconnected, self-supporting carbohydrate-glass lattice; (ii) stacked composition of 10T1/2
uniformly distributed in the fibrin gel and HUVECs in the vascular space; scale bar: 1 mm; (iii) cross-section image of a repre-
sentative channel; scale bar: 200 lm. Reproduced with permission from Ref. 77, copyright 2012 Nature Publishing Group.
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It has been long known that gelatin solutions
solidify at lower temperatures but liquefy at around
37 C, which allows for easy removal of gelatin-based
sacriﬁcial templates. Taking advantage of this unique
property of gelatin, 3D vascular channels were created
within a collagen I matrix by Dai et al.63 Interestingly,
due to the excellent biocompatibility of gelatin,
endothelial cells could be directly encapsulated within
the gelatin bioink during the bioprinting process. The
gelatin bioink diffused into the surround medium from
the channels over the course of culture at 37 C in an
incubator. After liquefying the gelatin template, the
endothelial cells were released from the gelatin ﬁbers
and could adhere to the interface between the liqueﬁed
bioink and the surface of the channels, where they
would eventually form a conﬂuent layer of endothe-
lium.
Another explored template material is carbohy-
drates, which could be fabricated into self-supporting
templates and subsequently removed by dissolving in
aqueous solutions. Carbohydrate glass lattices were
printed by Chen et al. as the sacriﬁcial template inside
a 3D hydrogel pre-polymer with encapsulated cells.77
After crosslinking the matrix, the carbohydrate lattice
simply dissolved using the culture medium (Figs. 3ei
and 3ii). The glass ﬁbers comprising of the lattice were
covered by a thin layer of PLGA to prevent during the
gel casting process. This carbohydrate sacriﬁcial
material was used in combination with a large variety
of synthetic ECM materials without showing
any negative effects on encapsulated cells, such as
HUVECs, 10T1/2 mouse embryo cells, human
ﬁbroblasts, and human embryonic kidney (HEK) cells.
The strong mechanical properties of the carbohydrate
glass rendered it possible to fabricate constructs at
larger scales containing multiple layers of intercon-
nected vasculature. It was further observed that, the
endothelialized microchannels were highly biomimetic,
where the coated endothelial cells could sprout into the
surrounding matrix to form neovessels with lumen
structures (Fig. 3eiii).
FORGING THE HEART
Heart is the ﬁrst functional organ formed during
embryonic development, when cells are conﬁned to
diﬀerent layers due to diﬀerential aﬃnities. Embryonic
mesoderm germ-layer cells then form the blood vessels,
the blood cells, as well as the heart (Fig. 4a).116 After
gastrulation, the embryonic mesoderm cell layer fur-
ther develops into mesothelium, endothelium, and
myocardium. Mesothelial pericardium derives into the
outer lining of the heart, while endothelium matures
into the inner lining of the heart, the lymphatic vessels
and the blood vessels.116 The main cellular components
that make up the heart include cardiomyocytes, car-
diac ﬁbroblasts, and endothelial cells.4,13,122 Previous
studies suggested that in a normal adult heart, car-
diomyocytes take up to 30–40% of the entire popula-
tion of the heart and the rest are non-myocytes with
the majority being ﬁbroblasts.85,122 At the tissue level,
heart is composed of three different types of cardiac
tissues: myocardium, endocardium, and peri-
cardium.116,122 The myocardium is the thick muscular
layer of the heart wall consisting of cardiomyocytes.
The sinoatrial node (SAN), a group of specialized
pacemaker cells located in the right atrium, can gen-
erate electrical impulses that set off contractions of
myocytes without any stimulation from the
nerves.116,122 Despite the intrinsic automaticity, this
pacemaker activity is normally controlled by opposing
input from the parasympathetic and sympathetic ner-
vous systems. The myocytes align themselves in an
anisotropic manner that promotes the electrical acti-
vation of the cardiac muscles.116,122 The endocardium
is the innermost layer of the heart chambers and heart
valves. It is primarily made up of endothelial cells that
form overlapping regions to seal the heart and connect
the surrounding blood vessels.116 Apart from pre-
venting the leakage, it also has the functions as blood-
heart barrier to ﬁlter certain types of molecules to enter
or exit the tissue. The pericardium is a double-wall
ﬁbroserous sac that encloses the heart and the root of
the blood vessels.116 The pericardial cavity, the space
between the two membranes of the pericardium, con-
tains pericardial ﬂuid that acts as lubricant to allow
membranes to slide over each other. Besides the three
major cardiac tissues, ECM also plays an important
role in shaping the fate of cells, regulating protein
expression and differentiation.23,96,97 In normal myo-
cardium, the elasticity of the collagen-based ECM and
cardiomyocytes must be matched to generate acto-
myosin forces and pump the heart.30
A number of techniques have thus been developed
to improve the functionality of engineered cardiac
tissues. Besides conventional tissue engineering
approaches, 3D bioprinting has recently shown to be a
promising alternative to produce functional cardiac
tissues, and particularly, the heart valves. The aortic
valve has a semilunar valves conformation with three
main components.116 The relatively stiff heart valve
root populated by contractile SMCs. Three thin ﬂexi-
ble leaﬂets contain ﬁbroblastic interstitial cells and
three sinuses. Along with the pulmonary valve, it al-
lows blood to be forced into the arteries and prevent
the backﬂows. It is crucial that the valves open and
close properly to keep the heart perform efﬁciently.
However, conventional options to treat dysfunctional
valves caused by stenosis or regurgitation, such as
3D Bioprinting for Tissue and Organ Fabrication
FIGURE 4. (a) Schematics showing the geographical anatomy of a mature human heart. Reproduced with permission from Ref.
117, copyright 2011 John Wiley & Sons. (b) Bioprinting of heart valves: (i) heart valve model designed by Solidworks; as-printed
valve conduit; Safranin-O staining to stain the glycosaminoglycans red which also stained the MeHA within the hydrogel red.
Reproduced with permission from Ref. 27, copyright 2014 Elsevier. (ii) Heterogeneous aortic valve e-printing software sliced the
geometries into layers and generated extrusion paths for each layer along with viable HAVIC-seeded valve scaffolds containing
cells across the entire surface of the conduits. Reproduced with permission from Ref. 26, copyright 2013 Wiley–VCH. (c) Cardiac
cells bioprinted in decellularized cardiac extracellular matrix. Scale bars: 5 mm and 400 lm. Reproduced with permission from Ref.
95, copyright 2014 Nature Publishing Group. (d) Bioprinting of the whole-heart structure: (i) A darkfield image of an explanted
embryonic chick heart. (ii) A confocal fluorescence micrograph of the heart stained for fibronectin (green), nuclei (blue), and F-
actin (red). (iii) The 3D CAD model of the heart with complex internal architecture based on the confocal data. (iv) A cross section of
the 3D bioprinted heart showing recreation of the internal trabecular structure from the CAD model. (v) A dark-field image of the 3D-
printed heart with internal structure visible through the translucent heart wall. Scale bars: 1 mm in (i) and (ii) and 1 cm in (iii) and
(iv). Reproduced with permission from Ref. 43, copyright 2015 American Association for the Advancement of Science.
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medication, surgical repair, and percutaneous balloon
valvotomy, have shown limited effectiveness. Heart
valve replacement is still one important procedure to
correct the symptoms.
Butcher et al. designed bioprinted trileaﬂet valve
hydrogels that regulate behaviors of encapsulated
human aortic vascular interstitial cells (HAVICs).27 In
this study, the geometries of the trileaﬂet valve were
designed by Solidworks (Fig. 4bi). Hybrid hydrogel
properties were varied by changing concentrations of
the two compositions: methacrylated hyaluronic acid
(MeHA) and GelMA. The optimized hydrogel for-
mulation was mixed with HAVICs and used as bioink
to print the heart valve conduit. After 7 days in static
culture, the bioprinted valve conduit showed well
maintained structure, high viability of the encapsulated
cells (>90%), as well as promising remodeling
potentials. This study expanded the range of bioma-
terials that could be used for bioprinting heart tissues
and provided an important understanding about the
bioprintable microenvironment architecture for con-
trolling HAVIC behaviors. Another study from the
same group successfully bioprinted an aortic valve
conduit with direct encapsulation of sinus SMCs in the
valve root and HAVIC in the leaﬂet (Fig. 4bii).26 The
3D model of the aortic valve was obtained by micro-
CT scan on the freshly harvest porcine aortic valves.
Live/Dead assay after 7 days of the encapsulated cells
in alginate/gelatin hydrogels showed 83.2 and 81.4%
viability for HAVICs and SMCs, respectively. More-
over, decreased cell circularity suggested high cell
spreading in both types of cells. This study proved that
3D bioprinting is capable of constructing a complex
heterogeneous aortic valve conduit.
Until now, however, the bioprinted aortic valves
have not been tested in a human body. Many studies
are being conducted toward implementation of clinical
trials. The bioprinted heart valves cannot open and
close by itself without the presence of the rest of the
heart. Hoerstrup et al. developed an in vitro cell culture
system that stimulated the heart valve with the physi-
ological pressure and ﬂow.28 Other than testing the
bioprinted heart valve, this stimulation also improved
the strength of the heart valve before a possible
implantation. Bioreactor systems have been used to
mature decellularized heart valves, which could be
beneﬁcial to bioprinted heart valves for in vitro testing
and maturation.
Myocardial infarction, another major cause of heart
failure, leads to congestive heart failure, derived by
irreversible necrosis of the heart muscle resulted from
prolonged ischemia to the myocardium.116 It was
commonly believed that cardiac muscle cells were ter-
minally differentiated cells and therefore did not have
the ability to regenerate.56 By using the C14 isotope
labeling technique, Bergmann et al. recently showed
that the cardiomyocytes could indeed renew, with an
annual turnover rate ranging from 1% at the age of 25
to 0.45% at the age of 75.5 The low renew rate, how-
ever, is insufﬁcient for repairing extensive myocardial
injuries that occur in human heart diseases and fully
regaining the functions of the heart.50 Currently, there
is no practical therapy to cure and recover injured
cardiomyocytes.
To this end, the capability to fabricate functional
myocardium for regeneration becomes crucial. Sluijter
et al. demonstrated that human cardiomyocyte pro-
genitor cells (hCMPCs) are capable of being bio-
printed and cultivated in alginate scaffolds for the
generation of myocardium constructs.36 Moreover,
cultured hCMPCs showed an increase of cardiac
commitment while at the same time maintaining via-
bility and proliferation (Fig. 4c). In another study, the
same group applied the laser-induced-forward-trans-
fer (LIFT) cell printing technique to fabricate a car-
diac patch made from polyesterurethane urea (PEUU)
with deﬁned patterns and seeded with co-cultured
HUVECs and human mesenchymal stem cells
(hMSCs).35 The bioprinted patches were transplanted
to the infarction area of rat heart and showed
increased vessel formation as well as signiﬁcant
functional improvement of the infarcted regions.
More recently, Feinberg et al. developed a 3D bio-
printing technology termed freeform reversible
embeddeing of suspended hydrogels, for fabrication
of complex biological structures.43 This method relied
on direct bioprinting of the bioinks into a support
bath of gelatin microparticles and took advantage of
the physical support by the supporting hydrogel un-
der room temperature to construct volumetric objects
at large scales that were impossible to achieve before.
The support bath could then be liqueﬁed at elevated
temperature to release the bioprinted structures.
Using this novel 3D bioprinting approach, the au-
thors demonstrated the capability to recapitulate the
complex trabecular structures of a whole heart
through CAD modeling (Fig. 4d).
BUILDING THE LIVER
Liver has the extensive capacity to regenerate even
with vast damages.75,113 The functional unit of liver is
the hepatic lobule, a hexagonally structured unit with a
side-to-side length of approximately 1 mm and a
thickness of around 2 mm (Fig. 5a).44,105 The lobules
carry on the crucial functions of complex exocrine and
endocrine metabolism and detoxiﬁcation. Millions of
lobules together constitute each of the Couinaud seg-
ments that make up the liver.44,105 The parenchymal
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hepatocytes have an endodermic origin and constitute
the major part of liver.33 Other cells that compose the
liver include portal ﬁbroblasts, sinusoidal endothelial
cells (SECs), and biliary epithelial cells. In addition,
there are mesoderm derived cells such as hepatic stel-
late cells (HSCs), stromal cells, and Kupffer cells.33,86
These non-parenchymal cells play signiﬁcant roles in
certain liver functions. For example, HSCs are heavily
involved in the synthesis of growth factors and regen-
eration of ECM proteins, both of which possess piv-
otal roles in hemostasis and cell signaling.107 Collagen
and glycosaminoglycan compose a considerable por-
tion of the ECMs that ensure the mechanical integrity
of hepatocytes and are responsible for providing
bioactive molecular signals to cells.62
Various techniques have been used over the past few
years to fabricate biomimetic liver tissues, starting
from 2D culture of parenchymal cells that showed
FIGURE 5. Bioprinting of liver tissues. (a) Layout of typical structural units of the hepatic lobule. In cross-sectional views, the
microstructures appear as a hexagonal lattice, with the hepatic artery, bile duct, and portal vein triads placed at the hexagon
vertices. Reproduced with permission from Ref. 117, copyright 2011 John Wiley & Sons. (b–d) Bioprinted liver tissue constructs
with similar arrangement of the hepatic lobules to native liver tissues and tissue-like cellular density and tight intercellular
junctions, using human primary hepatocytes, endothelial cells, and hepatic stellate cells. (b, c) Photographs showing the liver
organoids immediately after bioprinting. (d) Fluorescence micrograph of the planar cross-section after tissue maturation, high-
lighting the compartmentalization of the non-parenchymal cells relative to the hepatocytes. The hepatic stellate cells and
endothelial cells were pre-labeled in green and red, respectively, while the nuclei of all cells were stained in blue. Adapted with
permission from Ref. 103, copyright 2015 OrganovoTM.
ZHANG et al.
successful diﬀerentiation.62 With these simple tech-
niques, however, it was not possible to achieve the
microenvironment sufﬁcient for interactions between
the cells and the ECMs, and the cell survival rate was
thus limited. Further investigations in the ﬁeld sug-
gested that the intercellular adhesion is important,
leading to the development of several techniques to
construct volumetric liver tissues.54,55 Recently, 3D
bioprinting techniques have also been adopted to
fabricate liver-like microstructures. For example,
studies have exploited the possibility for 3D bioprint-
ing of hepatoma cells9,111 and hepatocytes118 using a
variety of hydrogels such as MeHA, PEG, gelatin, and
alginate in different combinations. Particularly, Orga-
novoTM, one of the ﬁrst bioprinting companies, has
successfully achieved 3D vascularized liver constructs
with high cell viability and reliable zonation through
bioprinting of high-density hepatocytes, endothelial
cells, and hepatic stellate cells in an architecture that
mimicked the native hepatic lobules (Figs. 5b–
5d).87,103 Alternatively, liver spheroids were used in
bioprinting to replace single hepatocytes. Using liver
spheroids can protect the cells from the negative effects
exerted by the shear stress during the printing process
and recapitulate the volumetric cell–cell interactions.9
The bioprinted liver spheroids embedded in GelMA
hydrogel exhibited long-term functionality for up to
30 days as revealed by their stable secretion of hepatic
biomarkers including albumin, ceruloplasmin, alpha-1
antitrypsin (A1AT), and transferrin. The liver spher-
oids, when combined with a microﬂuidic bioreactors,
successfully functioned as a viable platform to evaluate
hepatotoxic drugs, which induced dose- and time-de-
pendent responses of biomarker secretion by the or-
ganoids.
CONSTRUCTING THE CARTILAGE
Cartilages or cartilaginous tissues refer to the con-
nective tissues widely existing in vivo, constituting the
major components of joints between bones, ears, and
nose. In contrast to many other tissues, cartilaginous
tissues are featured by the avascular and aneural
structures containing a relatively low density of cells,
which limits the ability for the cartilages to sponta-
neously repair defects. Cartilage tissue engineering
aims to enhance regeneration by fabricating cell-laden
cartilage constructs for implantation. To this end, 3D
bioprinting offers unparalleled ability to deposit
bioinks and cells with precise spatial control, which
mimic the structural and compositional heterogeneity
of native cartilage tissues.
Since chondrocytes are the major cell type found in
cartilages, eﬀorts towards bioprinting 3D cartilage
tissues generally apply various designs of bioinks to
encapsulate chondrocytes and recreate the desired
shapes, from simple grid-like shapes to complex carti-
laginous tissues such as ears and noses. D’Lima and
Cui et al. applied photocrosslinkable PEG
dimethacrylate (PEGDMA) or GelMA as the bioinks
and demonstrated direct printing of human chondro-
cytes or hMSCs-laden constructs to repair cartilage
defects. The layer-by-layer bioprinting followed by
simultaneous crosslinking ensured homogeneous cell
distributions within the hydrogel matrix. High cell
viability and good integration of the bioprinted con-
structs with the defect smoothly interfaced the osteo-
chondral plug model.21,37
Similar with other organ bioprinting, one major
challenge in bioprinting 3D cartilage tissues lies in
ﬁnding proper bioink formulations with high bio-
compatibility and printability. For example, while
GelMA hydrogels are known to support chondrocyte
encapsulation, the prepolymer solutions typically
possess a low viscosity that impedes the ﬁdelity of
printed structures. To solve this issue, Malda et al.
reported the use of GelMA/hyaluronic acid (HA)
composites as bioinks to print cartilage constructs. The
addition of HA into GelMA prepolymer signiﬁcantly
increased viscosity of the resulting mixture, and thus
allowed direct extrusion of continuous hydrogel
strands that can further fuse into grid-like structures.
Histological and immunohistochemical staining of the
cell-laden constructs conﬁrmed glycosaminoglycan
formation and cartilaginous matrix production after
4 weeks in vitro culture.106 To increase printability and
structural ﬁdelity, Gatenholm et al. developed a com-
posite of cellulose nanoﬁbrils and alginate as a shear-
thinning bioink suitable for extrusion-based 3D bio-
printing. After printing, the constructs could be further
crosslinked in the presence of calcium. Human chon-
drocytes were encapsulated in this bioink to demon-
strate the printing of simple grid-like structures as well
as complex 3D anatomically shaped ear-like struc-
tures.73
Recently, Zenobi-Wong et al. reported successful
3D bioprinting of complex cartilaginous structures
using bioinks based on FDA-compliant materials:
gellan, alginate, and a commercial product Biocarti-
lage made of cartilage ECM particles.51 The composite
bioink showed excellent biocompatibility, and opti-
mized rheological properties including shear-thinning
and shear recovery. Various anatomically relevant
structures possessing auricular, nasal, and meniscal
shapes were demonstrated. The introduction of Bio-
cartilage promoted chondrocyte proliferation during
in vitro culturing, which also suggested versatility of
this method to print tissue-speciﬁc constructs using
different ECM components.51
3D Bioprinting for Tissue and Organ Fabrication
McAlpine et al. demonstrated that interweaving of
the 3D bioprinted cell-laden constructs with electronic
devices allowed fabrication of bionic artiﬁcial ears that
not only anatomically mimicked the ears, but also were
able to capture auditory signals. Cell-laden hydrogels
were bioprinted to form the structural part of the
bionic ear, which were integrated with a cochlea-
shaped electrode and a readout wire composed of silver
nanoparticle-infused silicone polymers. This study
suggested possible strategies to merge biological and
electronic functionalities via sophisticated 3D bio-
printing in conjunction with fabrication technology.71
CONCLUSIONS
Over the past few years, researchers not only have
demonstrated proof-of-concept examples of diﬀerent
bioprinting technologies, but also have shown possi-
bilities how 3D bioprinting may change the future of
tissue engineering, ranging from fabrication of organ
and tissue constructs for functional regeneration to
relevant models for pharmacological investigations.9,41
The 3D cell-embedding volumes of biomaterials gen-
erated by bioprinting could serve as biomimetic con-
structs with desired composition, structure, and
architecture to ensure better cell viability and more
importantly support the functionality of the tissues, as
demonstrated by numerous studies where tissues such
as vasculature, heart, liver, cartilage, bladder,34 and
skin10,66,110 have been bioprinted. Each of these tis-
sues/organs is highly complex and may require a
combination of several bioprinting techniques along
with speciﬁcally designed bioinks to introduce struc-
tural heterogeneity and functionality. For example the
sacriﬁcial bioprinting strategy may be integrated into
other deposition methods to produce hierarchically
vascularized tissues; and bioinks derived from tissue-
speciﬁc dECM may be ﬁtted on a multi-material bio-
printer to enable spatially deﬁned deposition of bioinks
that matches the architecture of the target organs to be
printed. Although challenges still present, with new
niches for technological developments on the instru-
mentation with improved spatial and temporal reso-
lutions as well as optimized bioinks and cell sources for
speciﬁc organs, it is expected that 3D bioprinting will
eventually become one of the most efﬁcient, reliable,
and convenient methods to biofabricate tissue con-
structs in the near future. Combination with the stem
cell technologies32,74,94 and advanced materials engi-
neering approaches featuring stimuli-responsive-
ness38,115 will further allow temporal evolution of
bioprinted tissue constructs that potentially meet the
requirements of dynamic tissue remodeling during
developmental processes.
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